Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron Inc. (NASDAQ: LGVN) announced that Dr. Chris Min, Interim CEO and Chief Medical Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City from September 12-14, 2022. The presentation is scheduled for September 13, 2022, from 8:30 to 9:00 a.m. ET. Interested parties can access the live webcast on Longeveron's website, with a replay available for 90 days. Longeveron focuses on cellular therapies for aging-related and life-threatening conditions, currently conducting Phase 1 and 2 clinical trials for various indications.
Longeveron Inc. (NASDAQ: LGVN) has received Fast Track Designation from the FDA for its investigational therapy Lomecel-B™. This therapy aims to treat Hypoplastic Left Heart Syndrome (HLHS), a rare congenital defect affecting about 1,000 infants annually in the U.S. Lomecel-B™ is currently undergoing a Phase 2a clinical trial. Fast Track Designation enhances interactions with the FDA, potentially accelerating approval. Notably, the ELPIS Phase 1 trial indicated 100% survival rate without heart transplants among participants.
Longeveron Inc. (NASDAQ: LGVN) announced the European Patent Office's intent to grant a patent for methods treating endothelial dysfunction with its cell therapy, Lomecel-B™. This patent, which focuses on monitoring efficacy through Vascular Endothelial Growth Factor (VEGF), reinforces Longeveron's intellectual property. The company aims to address various aging-related conditions and has received Rare Pediatric Disease Designation and Orphan Drug Designation for Lomecel-B™ targeting Hypoplastic Left Heart Syndrome. The patent is expected to expire in November 2035.
Longeveron (NASDAQ: LGVN) announced progress in its clinical trials, including a Phase 2a trial for Lomecel-B in Alzheimer’s patients, with 50% enrollment achieved. The Japanese PMDA accepted an amended trial design for Aging Frailty, potentially allowing accelerated market entry. The Phase 1/2 HERA trial noted met safety endpoints, showing promise for Lomecel-B. Financially, the company reported $27 million in cash as of June 30, 2022, sufficient to fund operations into 2024, although net losses increased to $5.6 million from $5 million year-over-year.
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology firm, announced that an abstract detailing the Phase 2a trial of Lomecel-B in Alzheimer’s Disease has been accepted for presentation at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. Ongoing enrollment for the trial is noted. Earlier in 2022, a peer-reviewed study confirmed the success of Lomecel-B in a Phase 1b trial, achieving its primary endpoint with good tolerability in patients. The poster presentation is scheduled for August 2, 2022.
Longeveron Inc. (NASDAQ: LGVN) reported its Q1 2022 financial results, highlighting a revenue of $0.4 million, consistent with Q1 2021. Clinical trial revenue increased by 88% to $0.3 million due to reduced COVID-19 travel restrictions, while grant revenue fell 72% to $0.1 million due to the completion of prior trials. R&D expenses rose by 6% to $1.4 million, and G&A expenses increased by 16% to $2.0 million, leading to a net loss of $3.5 million. Cash and short-term investments stood at $30.6 million. The company anticipates sufficient funds to cover expenses into H1 2024.
Longeveron Inc. (NASDAQ: LGVN) announced the resignation of CEO Geoff Green, effective June 1, 2022. K. Chris Min, M.D., Ph.D., the current Chief Medical Officer, will serve as Interim CEO while a nationwide search for a permanent successor takes place. Under Green's leadership, Longeveron progressed significantly, advancing their Lomecel-B therapy into clinical trials. The company specializes in cellular therapies targeting aging-related and life-threatening conditions and is pursuing Phase 1 and 2 trials for multiple indications including Alzheimer’s disease and frailty.
Longeveron Inc. (NASDAQ: LGVN) will release its first quarter 2022 financial results on May 13, 2022, before the U.S. market opens. The management will host a conference call at 8:30 a.m. EST on the same day to discuss the results and provide corporate updates. Longeveron is focused on developing cellular therapies for aging-related and life-threatening conditions. Its lead product, Lomecel-B, is currently in Phase 1 and 2 trials addressing multiple serious conditions. For more, visit longeveron.com.
Longeveron Inc. (NASDAQ: LGVN) announces participation in key events showcasing its commitment to developing cell therapeutics for aging-related diseases. Key presentations include: April 20 - Kevin N. Ramdas discusses Lomecel-B clinical trial results at ICFSR, Boston. April 21 - Anthony Oliva presents on cognitive frailty. April 25 - Ramdas presents at the Latinos & Alzheimer’s Symposium. April 26 - Joshua Hare presents on aging and frailty at Longevity Leaders World Congress, London. The Company aims to advance its therapies into Phase 3 trials for conditions like Alzheimer's and Aging Frailty.
Longeveron Inc. (LGVN) announced a new Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to add a Miami VA clinical site to its Phase 2 Alzheimer’s Disease trial. This collaboration marks the third CRADA with the VA, which also includes studies on aging frailty and Covid-19. The Phase 2 trial, named CLEAR MIND, will explore the safety and efficacy of Lomecel-B in treating mild Alzheimer’s, enrolling 48 patients. Recent peer-reviewed data indicated that Lomecel-B shows promise in slowing cognitive decline and improving quality of life.